Table 2.
Sample characteristics: Private payers with an explicit positive or negative coverage policy for next-generation tumor sequencing.
| Payer characteristic | Percentage (n = 69) |
|---|---|
| Size, in covered lives* | |
| 1 000 000 or more | 41 |
| Less than 1 000 000 | 59 |
| BlueCross BlueShield member | |
| Yes | 52 |
| No | 48 |
| Offer Medicare Advantage | |
| Yes | 72 |
| No | 28 |
| Adopted a third-party policy | |
| Yes | 22 |
| No | 78 |
*
Size is reported for lives covered by commercial insurance. Third-party policy is provided by a third-party laboratory benefit management company. Positive coverage policy states coverage of sequencing for any indication, any sequencing test(s), and any policy stipulation (eg, with or without prior authorization). Negative coverage policy states that sequencing is not covered for any indication or any sequencing test(s).